CVS — CVS Health Corporation

CVS Health Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Operating Income: $5.2 billion, up over 12% year-over-year.
• Adjusted Earnings Per Share (EPS): $2.57, an increase of over 14% from the prior year.
• Total Revenue: Exceeded $100 billion, a growth of over 6% compared to Q1 2025.
• Cash Flow from Operations: Approximately $4.2 billion.
• Medical Membership: Approximately 26 million, a sequential decline of 600,000 members due to exiting the Individual Exchange business.
• Medical Benefit Ratio (MBR): 84.6%, showing improvement from the prior year.

2. Strategic Updates and Business Highlights

• CVS is focused on improving affordability and reducing friction in healthcare delivery, particularly through its Aetna and Caremark segments.
• The company is enhancing its technology and operational efficiency, with initiatives like the Health100 platform aimed at creating a seamless healthcare experience.
• CVS is committed to value-based care and is actively engaging with regulators to address Medicare Advantage sustainability and pricing transparency.
• Innovations include the exclusion of branded STELARA in favor of biosimilars, aiming for significant cost savings for patients.
• Aetna has made strides in reducing prior authorization friction, with 95% of eligible requests approved within 24 hours.

3. Forward Guidance and Outlook

• Revised Full-Year 2026 Adjusted EPS Guidance: Increased to $7.30 - $7.50, up from $7.00 - $7.20.
• Total Revenue Expectation: At least $405 billion.
• Cash Flow from Operations: Expected to be at least $9.5 billion.
• Health Care Benefits Segment Adjusted Operating Income: Projected between $4 billion and $4.34 billion.
• Pharmacy & Consumer Wellness Segment Adjusted Operating Income: Expected to be at least $6.18 billion.

4. Bad News, Challenges, or Points of Concern

• Medicare Advantage Margins: Despite improvements, CVS acknowledges that current rates are insufficient to offset rising medical costs, leading to ongoing challenges in the Medicare business.
• Declining Medical Membership: The exit from the Individual Exchange business has resulted in a loss of members, which could impact future revenue.
• Regulatory Environment: Ongoing changes in state and federal regulations, particularly regarding PBM operations, could create uncertainty and operational challenges.
• Pharmacy Client Price Improvements: Continued pressure on margins due to pricing adjustments and regulatory impacts on drug pricing.

5. Notable Q&A Insights

• Medicare Advantage Rates: CVS expressed confidence in managing costs and improving margins, with a disciplined approach to growth and partnerships with CMS.
• Health Services Segment: The team indicated that early performance was encouraging, with a focus on rebate guarantees and managing pharmacy costs effectively.
• AI Investments: CVS is heavily investing in AI to enhance operational efficiency and improve consumer engagement, with expectations for these investments to yield benefits in the future.
• GLP-1 Market: CVS is focused on maintaining share in the GLP-1 market, emphasizing a robust direct-to-consumer strategy while managing costs effectively under the new pricing model.

Overall, CVS Health reported a strong start to 2026, with positive financial results and strategic initiatives aimed at enhancing healthcare delivery and affordability, despite facing challenges in membership and regulatory pressures.